PDT Partners LLC acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 25,303 shares of the company's stock, valued at approximately $426,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of CLBT. Verition Fund Management LLC increased its holdings in shares of Cellebrite DI by 20.6% in the 3rd quarter. Verition Fund Management LLC now owns 110,259 shares of the company's stock valued at $1,857,000 after acquiring an additional 18,859 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $9,274,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Cellebrite DI by 11.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 111,791 shares of the company's stock valued at $1,883,000 after acquiring an additional 11,730 shares during the last quarter. Tybourne Capital Management HK Ltd. bought a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $1,947,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $478,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently commented on CLBT. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $21.00 to $22.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Bank of America upped their price objective on Cellebrite DI from $13.00 to $17.00 and gave the stock a "buy" rating in a research note on Friday, August 16th. Craig Hallum upped their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Deutsche Bank Aktiengesellschaft upped their price objective on Cellebrite DI from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, August 16th. Finally, Needham & Company LLC upped their price objective on Cellebrite DI from $17.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $20.29.
Get Our Latest Stock Report on Cellebrite DI
Cellebrite DI Trading Up 3.0 %
CLBT stock traded up $0.61 during trading on Wednesday, reaching $21.01. 1,875,740 shares of the company's stock were exchanged, compared to its average volume of 1,193,159. The company's fifty day moving average price is $18.35 and its 200-day moving average price is $15.31. Cellebrite DI Ltd. has a 1-year low of $7.91 and a 1-year high of $21.14.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company's revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.09 earnings per share. As a group, research analysts expect that Cellebrite DI Ltd. will post 0.32 EPS for the current year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
